Chinese mRNA-based COVID vaccines effective in preclinical trials

0 Comment(s)Print E-mail Xinhua, June 12, 2022
Adjust font size:
A medical worker injects a dose of COVID-19 vaccine at a vaccination site of Jingcheng Hospital in Ruili City, southwest China's Yunnan Province, April 1, 2021. [Photo/Xinhua]

Two mRNA-based COVID-19 vaccine candidates produced by Chinese manufacturer CanSino Biologics have proven effective in preclinical trials, suggesting the potential for human tests, according to a new study published in the journal Emerging Microbes & Infections.

Results showed that the two vaccines, the mRNA-Beta and mRNA-Omicron, can induce high-titer neutralizing antibody levels against original and multiple SARS-CoV-2 variants, such as Beta, Delta and Omicron.

Two doses of mRNA-Beta could induce broad protection especially for Beta and original variants. Meanwhile, mRNA-Omicron was suggested as a booster injection in mice vaccinated with primary mRNA-Beta or Ad5-nCoV, the company's recombinant COVID-19 vaccine, to offer further protection against Omicron variant, according to the study.

The Chinese mRNA vaccines got clinical trial approval in April and they have entered phase-1 human trials, according to a company statement released this week.

Compared with traditional vaccine technologies, the mRNA technology has the advantage of a shorter development and production cycle.

The Chinese vaccine maker said an industrialization base of the COVID-19 mRNA vaccine was under construction in Shanghai. It will enable the annual production capacity to reach 100 million doses by the end of 2022.

Follow China.org.cn on Twitter and Facebook to join the conversation.
ChinaNews App Download
Print E-mail Bookmark and Share

Go to Forum >>0 Comment(s)

No comments.

Add your comments...

  • User Name Required
  • Your Comment
  • Enter the words you see:    
    Racist, abusive and off-topic comments may be removed by the moderator.
Send your storiesGet more from China.org.cnMobileRSSNewsletter